Silver Spring, MD – According to filings with the U.S. Securities and Exchange Commission, Aziyo Biologics is raising $13,999,975.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Ron Lloyd played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aziyo Biologics
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties. At Aziyo we believe an organizations potential is tied to the success and investment in its people. Strategy provides focus and goals for an organization, but a companys culture embodies the principles and values of the people and provides a philosophy to execute the strategic goals. We have adopted a set of guiding principles to help us navigate the challenges we face as a company so we can grow together.

To learn more about Aziyo Biologics, visit http://www.aziyo.com/

Contact:
Ron Lloyd, President and Chief Executive Officer
240-247-1143
https://www.linkedin.com/in/ronlloyd8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved